IMAGO BIOSCIENCES INC (IMGO) Stock Price, Forecast & Analysis
USA - NASDAQ:IMGO - US45250K1079 - Common Stock
IMGO Key Statistics, Chart & Performance
The current stock price of IMGO is 36.01 USD. In the past month the price increased by 0.25%. In the past year, price increased by 94.86%.
IMGO Latest News, Press Relases and Analysis
IMGO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.19 | 387.16B | ||
| AMGN | AMGEN INC | 14.64 | 172.38B | ||
| GILD | GILEAD SCIENCES INC | 14.51 | 147.46B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.59 | 104.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.61 | 69.69B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 868.04 | 58.03B | ||
| INSM | INSMED INC | N/A | 40.10B | ||
| NTRA | NATERA INC | N/A | 27.39B | ||
| BIIB | BIOGEN INC | 9.29 | 22.80B | ||
| INCY | INCYTE CORP | 16.51 | 20.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.01 | 20.30B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 36.45 | 15.11B |
Related stock screener links
About IMGO
Company Profile
Imago BioSciences, Inc. operates as a clinical-stage biopharmaceutical company that develops novel anti-cancer therapeutics. The company is headquartered in Redwood City, California and currently employs 41 full-time employees. The company went IPO on 2021-07-16. The firm is engaged in discovering and developing small molecule product candidates that target lysine-specific demethylase 1 (LSD1), an enzyme that plays a central role in the production of blood cells in the bone marrow. The company focuses on providing treatment for patients with cancer and bone marrow diseases. The Company’s lead product candidate is bomedemstat, which is developed for the treatment of myeloproliferative neoplasms (MPNs), a chronic cancer of the bone marrow. The Company’s product candidate, bomedemstat, is in Phase II clinical trial for the treatment of essential thrombocythemia (ET). The firm also develops bomedemstat and other LSD1-targeting product candidates for additional indications in areas of unmet medical need. The company tests bomedemstat in mouse models of MPNs as a single agent.
Company Info
IMAGO BIOSCIENCES INC
303 Twin Dolphin Drive, 6Th Floor
Redwood City CALIFORNIA US
CEO: Hugh Y. Rienhoff
Employees: 41
Phone: 14155295055.0
IMAGO BIOSCIENCES INC / IMGO FAQ
What does IMGO do?
Imago BioSciences, Inc. operates as a clinical-stage biopharmaceutical company that develops novel anti-cancer therapeutics. The company is headquartered in Redwood City, California and currently employs 41 full-time employees. The company went IPO on 2021-07-16. The firm is engaged in discovering and developing small molecule product candidates that target lysine-specific demethylase 1 (LSD1), an enzyme that plays a central role in the production of blood cells in the bone marrow. The company focuses on providing treatment for patients with cancer and bone marrow diseases. The Company’s lead product candidate is bomedemstat, which is developed for the treatment of myeloproliferative neoplasms (MPNs), a chronic cancer of the bone marrow. The Company’s product candidate, bomedemstat, is in Phase II clinical trial for the treatment of essential thrombocythemia (ET). The firm also develops bomedemstat and other LSD1-targeting product candidates for additional indications in areas of unmet medical need. The company tests bomedemstat in mouse models of MPNs as a single agent.
Can you provide the latest stock price for IMAGO BIOSCIENCES INC?
The current stock price of IMGO is 36.01 USD. The price increased by 0.03% in the last trading session.
Does IMAGO BIOSCIENCES INC pay dividends?
IMGO does not pay a dividend.
What is the ChartMill rating of IMAGO BIOSCIENCES INC stock?
IMGO has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the analyst forecast for IMGO stock?
11 analysts have analysed IMGO and the average price target is 36.72 USD. This implies a price increase of 1.97% is expected in the next year compared to the current price of 36.01.
What is the GICS sector and industry of IMGO stock?
IMAGO BIOSCIENCES INC (IMGO) operates in the Health Care sector and the Biotechnology industry.
What is the Price/Earnings (PE) ratio of IMAGO BIOSCIENCES INC (IMGO)?
IMAGO BIOSCIENCES INC (IMGO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.84).
IMGO Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to IMGO. When comparing the yearly performance of all stocks, IMGO is one of the better performing stocks in the market, outperforming 99.04% of all stocks.
IMGO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to IMGO. IMGO has a great financial health rating, but its profitability evaluates not so good.
IMGO Financial Highlights
Over the last trailing twelve months IMGO reported a non-GAAP Earnings per Share(EPS) of -1.84. The EPS decreased by -69.94% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
IMGO Forecast & Estimates
11 analysts have analysed IMGO and the average price target is 36.72 USD. This implies a price increase of 1.97% is expected in the next year compared to the current price of 36.01.